During a recent listening session at the FDA’s White Oak Campus in Washington, stakeholders voiced significant concerns regarding the Commissioner’s National Priority Voucher program, which was established by former FDA commissioner Marty Makary. This program allows for expedited reviews of drugs that align with national priorities, aiming for a review time of one to two months. While some representatives from patient groups and drug companies provided positive feedback, particularly those whose drugs had already received approval, the majority of speakers advocated for a pause in the program. They called for a reassessment of its processes, emphasizing the need for adherence to traditional regulatory procedures that involve public input. Critics of the program expressed apprehension regarding its potential for political interference, given the vague nature of the national priorities it seeks to address, which include tackling health crises and fostering innovative cures. The session underscored the need for transparency and public engagement in the drug approval process, reflecting a broader concern about maintaining the integrity of FDA operations.